Purpose: The purpose of the study is to evaluate the status of prescribed antihypertensives primarily during pregnancy, but also before pregnancy and after delivery, using a large claims database in Japan.
| INTRODUCTION
Hypertensive disorder of pregnancy (HDP) is one of the most common medical complications that arise during pregnancy. 1, 2 It is associated with life-threatening maternal obstetric complications and mortality, preterm delivery, fetal intrauterine growth restriction, low birth weight, and perinatal death. 3, 4 Thus, treatment with antihypertensive agents is common. 2, [5] [6] [7] [8] [9] Due to potential fetal adverse outcomes of drug exposure, the potential toxicity of antihypertensives to the fetus is important to determine. However, little is known about antihypertensive agents prescribed to pregnant women in Japan. Studies of antihypertensive drug prescriptions during pregnancy should provide important indicators of the drugs that are most commonly prescribed to pregnant Japanese women and facilitate programs to optimize antenatal prescriptions.
Health administrative databases are important sources of data that are used worldwide for pharmacoepidemiological evaluations of exposure to drugs during pregnancy and associated risks. These databases have many advantages including size, accurate medication data derived from prescription claims, the elimination of recall bias, and an accurate reflection of actual clinical practice. 8, 10, 11 Japanese health administrative databases are also useful for pharmacoepidemiological research (Japanese Society of Pharmacoepidemiology; databases for pharmacoepidemiology research in Japan: http://www.jspe.jp/mtstatic/FileUpload/files/JSPE_DB_TF_E.pdf).
We developed algorithms to identify dates of pregnancy onset and delivery from administrative data. 12 The primary objective of the present study was to clarify trends in antihypertensive drugs prescribed for women during pregnancy by applying these algorithms to data from a large administrative database. As well as this primary objective, we also summarized the trends before pregnancy and after delivery to determine prescription timing and choices of drugs during each of the three periods.
| METHODS

| Data source
We extracted information from a large database of health insurance claims developed and maintained by the Japan Medical Data Center (JMDC). 13 The database includes all inpatient, outpatient, and pharmacy claims received from insurers, and it is one of the largest data- and obvious errors in date entries). The database was processed into a standardized format, and individual data were rendered innominate.
| Study population
Mothers can be linked with their offspring in the JMDC claims database if their infants are covered by the same health insurer. This allows identification of the month and year of birth (the date of birth is not available to avoid identification). We used a dataset available on February 27, 2017, which included 3 836 202 men and women covered by health insurance between January 2005 and August 2016. We selected information about women who met the following eligibility criteria to evaluate prescriptions during pregnancy: mothers whose infants were covered by the same health insurer during their birth month, mothers who had been covered exclusively by one of a number of health insurers for 10 months before and during the birth month of their infants (11 months in total), and those whose dates of pregnancy onset and delivery could be identified. We evaluated prescriptions during pregnancy in this population. We also evaluated prescriptions in a subpopulation of women who were covered by the same health insurers from 180 days before pregnancy through 180 days after delivery.
| Identification of pregnancy onset and delivery date
Neither dates of pregnancy onset nor delivery are available in Japanese claims. The onset of pregnancy was estimated by subtracting gestational age at the time of a specific visit recorded as part of a diagnosis, from the date of the diagnosis. For example, when "delivery at week 39" was entered, then 39 weeks and 0 days was subtracted. If a woman had several visits with diagnoses specifying gestational age during pregnancy, the most recent gestational age was applied, given that the later stage of pregnancy usually provides a more accurate gestational age. Likewise, if two or more pregnancies were identified for one woman, we used only data from one pregnancy, the one with
KEY POINTS
• The prevalence, timing, and type of antihypertensive drugs prescribed for pregnant women in Japan were determined using information extracted from a large database of insurance claims.
• At least one antihypertensive agent was prescribed for 1144 (2.74%) of 41 693 pregnant women.
• Based on evaluation of 33 941 pregnant women, the number of prescriptions for antihypertensives increased, particularly during the third trimester, then decreased from 91 to 180 days after delivery.
• The effects of exposing pregnant Japanese women to these agents should be evaluated. case, the first day of the birth month was considered as the delivery date ( Figure 1 ).
When the difference between the dates of pregnancy onset and delivery identified by the algorithm exceeded 294 days, a gestational period of 294 days was uniformly assigned, and the onset of pregnancy was regarded as 294 days before the claim-based delivery date. Pregnancies were divided into the first (from pregnancy onset to week 13 of gestation), second (weeks 14 through 27), and third (from week 28 until delivery) trimesters. 
| Prescriptions for antihypertensives
All prescriptions for antihypertensives were included in the analyses.
We primarily used the dispensed date and, if unavailable, the admission date. As the month and year were available for each claim, each drug was assigned to the 15th day of the month when either of these dates was missing. The duration of prescriptions was also considered to determine the timing of exposure. The antihypertensives listed in Supplementary Table 2 
| Data analyses
The prevalence of antihypertensive drug prescriptions during pregnancy was descriptively evaluated, then calculated for each trimester and for each delivery-based year. Time trends of antihypertensive drugs and their classes prescribed for >10 women during pregnancy were evaluated using multivariate logistic regression analyses and adjusted by age at delivery using the Bonferroni correction. The cutoff for significance was set at 0.00263 (0.05/19). We assessed the robustness of the findings using two sensitivity analyses with slight modifications in the method used to identify delivery dates.
In one of these analyses, we modified only the definition of the delivery date to day 15 of the birth month instead of the first day when delivery-related information was missing and repeated the evaluation of antihypertensive drug prescriptions during pregnancy. In the other, we used only selected delivery-related diagnoses and surgical procedures to identify delivery dates, whereas all delivery-related diagnoses and surgical procedures listed in Supplementary Table 1 were originally applied. To further understand precisely who received antihypertensives, we additionally evaluated prescriptions during pregnancy in the same manner for those diagnosed with HDP defined as ICD-10 code O10-O16
(edema, proteinuria, and hypertensive disorders in pregnancy, childbirth, and the puerperium).
The prevalence of antihypertensive drug prescriptions was evaluated for 180 days before pregnancy, during pregnancy, and 180 days after delivery among women who were covered by the same health FIGURE 1 Algorithms to identify delivery dates. If two or more delivery-related entries were available for one woman, the most recent date was considered as the delivery date. *"Selected" deliveryrelated diagnoses and surgical procedures defined as follows: (1) diagnoses with selected ICD-10 codes (O60, O622, O629, O640, O655, O669, O683, O690, O709, O711, O717, O721, O723, O730, O800, O814, or O821) for which dates of diagnosis are available and (2) selected surgical procedures (vacuum extractions, cesarean section, and obstetric hysterectomy) with execution date available. ICD-10, International Classification of Diseases 10th Revision insurer during the entire period. Prescription prevalence was also calculated for 180 to 91 days and from 90 to 1 day before pregnancy, and from 1 to 90 days and from 91 to 180 days after delivery. To evaluate the trends in treatment with antihypertensives during pregnancy among women taking antihypertensives before pregnancy, we summarized the prevalence of antihypertensive prescriptions during pregnancy among women who were prescribed antihypertensives within 180 days before pregnancy. All data were analyzed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
| RESULTS
Among 3 836 202 individuals, 1 742 958 were women, and of these, 76 843 were linked to their children ( Figure 2 ). Of those, 48 984 were covered exclusively by the same health insurer for 10 months before and during the birth month of their children, (11 months in total).
Among them, at least one entry specifying gestational age was avail- Table 3 ). The most frequently prescribed oral antihypertensive was nifedipine (0.67%), followed by methyldopa Table 5 ).
Among the 41 693 women, 33 941 had been covered exclusively by one health insurer from 180 days before pregnancy until 180 after delivery. Table 1 shows the characteristics of this population. The number of prescribed antihypertensives increased particularly during the third trimester, then decreased from 91 to 180 days after delivery (Table 3 ). The prevalence of oral antihypertensive drug prescriptions was the highest during the first 90 days after delivery, whereas that of injectable drug prescriptions was the highest during the third trimester. The most frequent oral antihypertensive classes prescribed before pregnancy were dihydropyridine calcium antagonists (0.09%), β blockers (0.07%), ARB (0.05%), and central agonists (0.04%). The prevalence of prescriptions for injectable antihypertensive drugs before pregnancy was very low (Table 3 and Supplementary Table 6 ).
Oral dihydropyridine calcium antagonists were the most frequently prescribed after delivery (1. 
| DISCUSSION
This is the first evaluation of the status of antihypertensives prescribed for pregnant women in Japan based on information derived from a large database of insurance claims.
The prescription rates of antihypertensives were 0.23% and 2.74% during the first trimester and during the entire pregnancy, respectively. The prevalence of antihypertensives reported from the Japan Environment and Children's Study 16 is likely to be lower than the present study, as the study design and observation period differed between the Japan Environment and Children's Study and the present study and the results of the 2 studies cannot be equitably compared.
The reported prevalences of antihypertensive medications elsewhere during the first trimester are 1.5% in the UK 7 and 1.2% to 1.9% in the USA, 8,9 and 3.1% to 4.4% throughout pregnancy in the USA.
8,9
The prevalence of antihypertensive medications used by pregnant women might be lower in Japan than elsewhere. Blood pressure is lower in non-Europeans than Western Europeans during early pregnancy. 17 Ethnic differences affect the prevalence and severity of hypertensive diseases during pregnancy, and Asian/Pacific Islanders have a lower risk of hypertension during pregnancy. 18 These differences might be associated with the lower rate of prescribed antihypertensives in Japan. One report from the UK describes regional variations in the use of antihypertensives for preeclampsia, 19 and regional variations might also be similar in Japan. We also found that found that nifedipine was already in use. 20 This indicates that nifedipine has frequently been applied, presumably to treat severe HDP, based on experience and guidelines rather than package insert information.
We found that oral labetalol was rarely prescribed. Labetalol and methyldopa are sympathetic blocking agents with the same mechanism of action. Therefore, guidelines do not recommend concurrent use of these two drugs. 2, 5 Furthermore, labetalol was contraindicated for pregnant women in the package insert until 2011. Therefore, labetalol may not have been frequently prescribed in Japan.
The present study showed that furosemide is relatively frequently prescribed for pregnant women, although the annual frequency has significantly decreased. Furosemide is not contraindicated in the package insert in Japan, whereas the Japanese guidelines state that diuretics are not appropriate for use during pregnancy because they may decrease fetal-placental blood flow. 5 Diuretics are also used to treat cardiomyopathy and heart failure as well as hypertension. The reported incidence of peripartum cardiomyopathy (PPCM) is 1:300 to 1:4000 pregnancies. 21, 22 A review of PPCM management noted that some patients with PPCM require thiazide diuretics or furosemide before delivery. 23 Our data might have included pregnant women who had cardiovascular diseases.
Drugs targeting the RAS are contraindicated during the second and third trimesters. However, they are prescribed for pregnant women, and the present study found that some might have been prescribed during the second and third trimesters. Some RAStargeting agents might have been prescribed before pregnancy, or for advanced postpartum blood pressure management. Such drugs can worsen pregnancy outcomes and increase the risk of neonatal malformations, [24] [25] [26] [27] [28] although one study found that RAS-targeting agents do not worsen pregnancy outcomes. 29 More information is needed about the risk conferred by drugs targeting the RAS conferred upon pregnant women.
Nicardipine was the most frequently prescribed injectable antihypertensive during pregnancy, followed by furosemide, hydralazine, and nitroglycerin. These findings were consistent (except for furosemide) with the recommendations in the Japanese guidelines indicating the application of intravenous antihypertensive therapy to hypertensive emergencies. 2, 5 The annual number of organic nitrate prescriptions for pregnant women has significantly increased.
Intravenously infused nitroglycerin was reported during 2008 as being an effective, safe, and alternative agent for treating severe preeclampsia, 30 and it has been listed as one choice of injectable antihypertensive for HDP in the Japanese guidelines since 2014. 2, 5 This might have led to the significant increase of the number of prescriptions for organic nitrates. We assessed this limitation using sensitivity analyses, but they might not have adequately addressed this matter. The study population Data are shown as n (%). Please see Supplementary Table 6 for the prevalence of antihypertensives and their classes prescribed to <50 and <20 women, respectively.
a Denominator of percentages is number of pregnant women who reached third trimester (n = 33 828).
included only those with live-born children who were covered by the same health insurer as their mothers because an algorithm with which to directly identify pregnancy without a child has not been developed and validated. Thus, we could not evaluate drugs prescribed to women whose pregnancy ended in abortion or stillbirth. Although we evaluated time trends, the counts of deliveries in earlier years might be too low to estimate prescribed antihypertensives, particularly for individual agents.
In conclusion, various types of antihypertensive agents are prescribed for pregnant women in Japan. The effects of these agents on pregnant Japanese women should be evaluated.
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